Study #2021-0802
A Phase II Study of the Combination of Ponatinib with Mini-hyper CVD Chemotherapy and Venetoclax in Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
MD Anderson Study Status
Not Accepting
Treatment Agent
Ponatinib, Venetoclax, Mini-hyper CVD
Description
The addition of ponatinib to mini-hyper-CVD chemotherapy and venetoclax will improve the complete remission rate in patients with relapsed or refractory T-cell acute lymphoblastic leukemia
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Acute Lymphoblastic Leukemia, Leukemia
Study phase:
Phase II
Physician name:
Nitin Jain
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.